

Customer:
HELIO

EA Sample ID: 26EA0623-294
Sample Name: IGF-1 LR3 1mg
Sample Type: Lyophilized Powder
Batch/Lot: 26144001

Date Received:
06/23/2026
Date Completed:
07/08/2026



CERTIFICATE OF ANALYSIS

Summary of Results

Analysis Type	Method	Date Tested	Status
Purity & Quantitation	RP-HPLC	07/08/2026	Pass
Identity	HPLC-RTM	07/08/2026	Pass
Endotoxin	USP <85>	07/08/2026	Reported



Serving Size: N/A

Peptide Analysis

Analyte	Specification	Result	Status
Peptide Purity (HPLC)	≥ 95.0%	98.31%	PASS
Net Peptide Content	Report Only	1.04 mg	N/A
Identity (HPLC-RTM)	IGF-1 LR3	Confirmed	PASS
Fentanyl Screen	Immunoassay, 50 ng/mL cutoff	Not Detected	PASS
Endotoxin (USP <85>)	Report Result	NMT 0.05 EU/mL	Reported

Notes & Methodology

- The sample was confirmed to be IGF-1 LR3 by HPLC, identified by chromatographic retention time comparison with a reference standard.
- Endotoxin tested per USP <85> kinetic turbidimetric method; reported as a quantitative value, with acceptance criteria per client specification.
- Peptide purity determined by RP-HPLC area normalization at 214 nm. The value represents the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process-related impurities, if detected, are excluded from the calculation.

LOD = LIMIT OF DETECTION; LOQ = LIMIT OF QUANTIFICATION

Ethos Analytics Laboratory
3020 E Camelback Rd STE 397
Phoenix, AZ 85016
Info@Ethosanalytics.io
www.Ethosanalytics.io
Lic #: 000026LRCND60176649
ISO/IEC 17025 Acc #: 117798




Noel Samsum
Laboratory Director
08-Jul-2026

The sample analyzed was inspected and is free from visual mold, mildew, and foreign matter. The testing procedures, equipment calibration, and maintenance are all in accordance with ISO/IEC 17025:2017 standards. The presented report is only applicable to the sample specified above and may not be applied to any similar or identical products. Reports are prohibited from being reproduced with alterations of any kind.